Intralytix ™s CEO, John Woloszyn, further added: "In addition to supporting the development of an exciting new product, we believe that the data obtained during the grant will enable us to develop a completely new line of phage-based products for Intralytix ™s portfolio. He added that: "Using bacteriophages as probiotic/nutraceutical products is a novel idea, and our company holds a patent for using phages to reduce bacterial colonization, including colonization of the GI and nasal tracts. If the studies performed during our Phase I project are successful “ as we fully anticipate “ they will provide a strong basis for moving forward with Phase II grant support from the Army, which will play a major role in bringing this exciting technology and product closer to the marketplace. Mr. Woloszyn also noted that Army grants have previously supported and continue to support Intralytix ™s development of other phage-based products, including food additives that protect food from contamination by E. coli O157:H7, Salmonella and Shigella, and a preparation for treating Acinetobacter baumannii-infected wounds. Finally, he noted that, while the U.S. Army ™s Research Office supports the project, such support does not necessarily reflect the position or the policy of the U.S. Government, and no official endorsement should be inferred.

Source: Intralytix, Inc.